Trial Information
Vaginal DHEA to Ease Vaginal Dryness in Women With a Contraindication to Estrogen Therapy
Inclusion Criteria:
- women post menopausal aged 35-55, suffering from vaginal dryness, secondary to
chemotherapy for breast cancer, within 5 years of diagnosis. Follicle Stimulating
Hormone and Estradiol levels in the post menopausal range are needed.
Exclusion Criteria:
- women using products to alleviate vaginal dryness.
- women taking medication for urinary incontinence
- women not sexually active, for other reasons.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
improvement in vaginal dryness
Outcome Time Frame:
12 weeks
Safety Issue:
No
Principal Investigator
Drorith Hochner-Celnikier, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Hadassah Medical Organization
Authority:
Israel: Ministry of Health
Study ID:
DHEA-HMO-CTIL
NCT ID:
NCT01724242
Start Date:
February 2013
Completion Date:
December 2014
Related Keywords:
- Vaginal Dryness
- Breast Cancer
- Urinary Incontinence
- Quality of Life
- Sexual Satisfaction
- Vaginal dryness
- Breast Cancer
- Urinary Incontinence
- Quality of Life
- Sexual Satisfaction
- Breast Neoplasms
- Urinary Incontinence